Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice-Reference-Cited by-同舟云学术

Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice

Published:2013-08 Issue:8 Volume:54 Page:2195-2205
ISSN:0022-2275
Container-title:Journal of Lipid Research
language:en
Short-container-title:Journal of Lipid Research

Author:

Gautier Thomas,de Haan Willeke,Grober Jacques,Ye Dan,Bahr Matthias J.,Claudel Thierry,Nijstad Niels,Van Berkel Theo J.C.,Havekes Louis M.,Manns Michael P.,Willems Stefan M.,Hogendoorn Pancras C.W.,Lagrost Laurent,Kuipers Folkert,Van Eck Miranda,Rensen Patrick C.N.,Tietge Uwe J.F.

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Biochemistry

Reference47 articles.

1. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis;Masson;J. Lipid Res.,2009

2. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis;Barter;Arterioscler. Thromb. Vasc. Biol.,2003

3. Translating molecular discoveries into new therapies for atherosclerosis;Rader;Nature.,2008

4. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study;Boekholdt;Circulation.,2004

5. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction;Zeller;J. Am. Coll. Cardiol.,2007

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases;Seminars in Immunology;2024-02

2. Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease;Biomedicines;2023-10-03

3. Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling;Nutrients;2023-03-02

4. Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: a systematic review and meta-analysis;RPS Pharmacy and Pharmacology Reports;2022-09-01

5. Recent advances on FXR-targeting therapeutics;Molecular and Cellular Endocrinology;2022-07